Radiation Oncology/Radiobiology/Hypoxia

From Wikibooks, open books for an open world
Jump to navigation Jump to search


Hypoxia


Overview[edit | edit source]

  • Oxygen "fixes" (makes permanent) damage caused by free radicals (ion pair -> free radical -> DNA damage -> O2 fixation by making permanent DNA-peroxide bond)
    • Must be present during or immediately (~5 msec) after RT
  • Oxygen enhancement ratio (OER) ~2.5x
    • Decreases with increasing LET: photons 2.5, neutrons 1.5, alpha 1.0
    • Similarly, decreases with increasing RBE
    • For photons, increases with dose and dose rate. If dose/fx <2 Gy OER ~1.5x, if dose/fx >2 Gy OER ~3x
  • Measurements of oxygenation
    • Evaluated directly by polarographic Eppendorf oxygen probes
    • Exogenous: Nitroimidazoles (reduced and irreversibly bound under low O2 tension), EF5, carbon black
    • Endogenous compounds: carbonic anhydrase (CA9), HIF, GLUT1 (need biopsy)
    • Noninvasive imaging: PET F-18-miso, PET Cu-64-Cu-ATSM, SPECT I-123-azomycin arabinoside
  • Hypoxia markers:
  • O2 concentration
    • Air 155 mmHg, 100% oxygen 760 mmHg
    • O2 tension in tissues varies between 1 - 100 mmHg, venous blood ~30 mmHg. Many tissues normally borderline hypoxic
    • Cell survival very sensitive to low level O2. At 0.2% O2 (1 mm Hg), survival curve noticeably different
    • At 0.5% O2 (3 mm Hg), survival halfway to aerated
    • Most rapid change between 0 and 30 mmHg
    • Virtually no change in survival curve from venous to arterial to 100% oxygen
  • O2 diffusion distance in metabolic active tissue 100-200 µm (Tomlinson-Gray hypothesis, PMID: 13106296)
  • Hypoxia varies
    • Spatially: within tumor
    • Temporary: chronic (diffusion-mediated due to distance from blood vessels) vs acute (perfusion-mediated due to transient fluctuations in blood flow due to malformed vascular supply)
    • From patient to patient
  • Hypoxic fraction
    • Can estimate by extrapolating back from shallow portion of the biphasic survival curve (steep portion is for oxygenated and shallow portion is for hypoxic cells)
    • Ranges from 0-50%, on average ~15%
  • Reoxygenation
    • RT preferentially kills oxygenated cells. Hypoxic cells survive, but typically become re-oxygenated within 24 hours, just in time for the next fraction
    • Therefore, if re-oxygenation is achieved, hypoxic cells do not have a significant effect on outcome of fractionated RT
    • Lack of reoxygenation is potentially a concern for single fraction SRS/SBRT treatment approaches
    • The extent and rapidity of re-oxygenation varies dramatically from tumor to tumor, and depend on proportion of chronic vs acute hypoxia present
  • Hypoxic conditions may play a role in malignant progression, by decreasing apoptosis, increasing genomic instability and gene amplification, and by promoting angiogenesis
  • Radiosensitization of hypoxic cells
    • Improved oxygen delivery: Hyperbaric oxygen, perfluorocarbons, carbagen
    • Tobacco cessation
    • Drugs: nitroimidazoles (misonidazole showed limited effect, nimorazole significant improvement in a Danish H&N trial) for chronic hypoxia, nicotinamide for acute hypoxia
    • Concurrent chemo: Mitomycin C, Tirapazamine
  • Hypoxia imaging (PMID: 28540739): the principal noninvasive approaches to imaging tumor hypoxia currently include magnetic resonance and radionuclides (PET and single-photon emission computed tomography), but other techniques, such as optical imaging or electron spin resonance, are under investigation
  • Angiogenesis (see more below):
    • Pro-angiogenesis: HIF-1α, VEGF, PDGF, FGF
    • Anti-angiogenesis:
      • Natural: VHL, TSP-1, Angiostatin, Endostatin, Heparin
      • Drugs: bevacizumab, sunitinib, sorafenib, thalidomide

Hypoxia Inducible Factor (HIF)[edit | edit source]

  • HIF proteins are a constitutively expressed family, including HIF-1α, HIF-1β, and HIF-2α
  • EGLN2 enzyme acts as a cellular oxygen sensor. It is a prolyl hydroxylase (PHD)
    • Under normoxic conditions, it hydroxylates HIF-1α using available oxygen
    • Hydroxylated HIF-1α is recognized by Von Hippel-Lindau (VHL) protein, and marked for degradation by ubiquination
    • Under hypoxic conditions EGLN2 does not have access to oxygen, and thus does not hydroxylate HIF-1α
  • HIF-1α subsequently binds to HIF-1β, and the complex acts as a transcription factor on DNA hypoxia-responsive elements (HREs). Targets include
    • VEGF: promotes angiogenesis
    • GLUT-1: promotes glycolysis and oxygen-independent ATP production
    • Stimulation of erythropoiesis
    • Increase in apoptosis by interaction with Bcl-2 protein family and p53
  • However, HIF-1α levels are also influenced by Ras and PI3K pathways, so that HIF-1α activity may not directly correlate with hypoxia


Review

  • Duke 2005 PMID 16098463 -- "Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity." (Moeller BJ, Cancer Cell. 2005 Aug;8(2):99-110.)
    • Radiation increases HIF-1 activity in tumors, both sensitizing and protective:
      • Radiosensitization: promotes ATP metabolism, proliferation, p53 activation
      • Radioresistance: stimulates endothelial cell survival
    • Net effect of HIF-1 blockade highly dependent on treatment sequencing, with "radiation first" being more effective due to preventing development of radioresistance effect
    • Comment from MSKCC PMID 16098459


Vascular Endothelial Growth Factor (VEGF)[edit | edit source]

  • Family of proteins resulting from alternate splicing of mRNA from a single VEGF gene
  • Bind to tyrosine kinase receptors (VEGF-R) on cell surface, causing them to dimerize
  • VEGF-R2 appears to modulate most known cellular responses
    • Angiogenesis (endothelial cell migration, mitosis, creation of blood vessel lumen, fenestrations, etc)
    • Chemotaxis for macrophages and granulocytes
    • Vasodilation through NO release
  • VEGF-R3 appears to mediate lymphangiogenesis
  • Anti-VEGF therapies


Lymphangiogenesis[edit | edit source]

  • 2007 PMID 17878481 -- "Role of lymphangiogenesis in cancer." (Sundar SS, J Clin Oncol. 2007 Sep 20;25(27):4298-307.)
    • Review